Evidence map›Paper›PMID 25588042›Full record

ArticlePloS one2015

The baculovirus-expressed binding region of Plasmodium falciparum EBA-140 ligand and its glycophorin C binding specificity.

Joanna Rydzak, Radoslaw Kaczmarek, Marcin Czerwinski, Jolanta Lukasiewicz, Jolanta Tyborowska, Boguslaw Szewczyk, Ewa Jaskiewicz

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Malaria: past, present, and future.Signal transduction and targeted therapy · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Joanna RydzakLudwik Hirszfeld Institute of Immunology and Experimental therapy, Polish Academy of Sciences, Wroclaw, Poland.
Radoslaw KaczmarekLudwik Hirszfeld Institute of Immunology and Experimental therapy, Polish Academy of Sciences, Wroclaw, Poland.
Marcin CzerwinskiLudwik Hirszfeld Institute of Immunology and Experimental therapy, Polish Academy of Sciences, Wroclaw, Poland; Faculty of Physiotherapy and Physical Education, Opole University of Technology, Opole, Poland.
Jolanta LukasiewiczLudwik Hirszfeld Institute of Immunology and Experimental therapy, Polish Academy of Sciences, Wroclaw, Poland.
Jolanta TyborowskaDepartment of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Boguslaw SzewczykDepartment of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Ewa JaskiewiczLudwik Hirszfeld Institute of Immunology and Experimental therapy, Polish Academy of Sciences, Wroclaw, Poland; Department of Molecular Biology, University of Zielona Góra, Zielona Góra, Poland.
Gdańsk Medical University · PLLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PLPolish Academy of Sciences · PLUniversity of Zielona Góra · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The erythrocyte binding ligand 140 (EBA-140) is a member of the Plasmodium falciparum DBL family of erythrocyte binding proteins, which are considered as prospective candidates for malaria vaccine development. The EBA-140 ligand is a paralogue of the well-characterized P. falciparum EBA-175 protein. They share homology of domain structure, including Region II, which consists of two homologous F1 and F2 domains and is responsible for ligand-erythrocyte receptor interaction during invasion. In this report we describe, for the first time, the glycophorin C specificity of the recombinant, baculovirus-expressed binding region (Region II) of P. falciparum EBA-140 ligand. It was found that the recombinant EBA-140 Region II binds to the endogenous and recombinant glycophorin C, but does not bind to Gerbich-type glycophorin C, neither normal nor recombinant, which lacks amino acid residues 36-63 of its polypeptide chain. Our results emphasize the crucial role of this glycophorin C region in EBA-140 ligand binding. Moreover, the EBA-140 Region II did not bind either to glycophorin D, the truncated form of glycophorin C lacking the N-glycan or to desialylated GPC. These results draw attention to the role of glycophorin C glycans in EBA-140 binding. The full identification of the EBA-140 binding site on glycophorin C molecule, consisting most likely of its glycans and peptide backbone, may help to design therapeutics or vaccines that target the erythrocyte binding merozoite ligands.

Indexed as

BaculoviridaeCarrier ProteinsErythrocytesGlycophorinsMalaria, FalciparumMalaria VaccinesMembrane ProteinsPlasmodium falciparumProtein BindingProtozoan ProteinsCarrier ProteinsEBA140 protein, Plasmodium falciparumGlycophorinsMalaria VaccinesMembrane ProteinsProtozoan Proteins

Identifiers

PMID25588042
PMCPMC4294638
OpenAlexW2032908421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.